Allergan to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical Dermatology Conference

DUBLIN, Oct. 11, 2017 /PRNewswire/ -- Allergan (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 22 abstracts at the 2017 Fall Clinical Dermatology Conference (FCDC) in Las Vegas from October 12-15. Among the highlights are new presentations on acne and ongoing redness associated with rosacea, containing efficacy data on ACZONE^® (dapsone) Gel, 7.5% and RHOFADE^® (oxymetazoline hydrochloride) CREAM, 1%.

"We are pleased to share a variety of data from across our facial aesthetic and medical dermatology portfolios," said David Nicholson, Ph.D., Chief Research and Development Officer, Allergan. "Our open science model continues to reinforce our commitment to advancing research and being at the forefront in medical dermatology."

The following posters will be displayed from Oct 13^th through 1PM, October 15^th:

• Long-term Topical Oxymetazoline Hydrochloride 1.0% Demonstrates Sustained and Increasing Effect in Persistent Facial Erythema of Rosacea. Authors: Gold M, et al.
• Topical Oxymetazoline Hydrochloride 1.0% Effectively Reduces Persistent Facial Erythema of Rosacea on Day 1. Authors: Tanghetti E, et al.
• Once-Daily Topical Dapsone Gel 7.5% Is More Effective in Females Regardless of Baseline Acne Lesion Count. Authors: Tanghetti E, et al.
• Efficacy and Safety of OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Subjects With Upper Facial Lines. Authors: De Boulle K, et al.
• Efficacy and Safety of OnabotulinumtoxinA for Treatment of Moderate to Severe Forehead Lines. Authors: Fagien S, et al.
• OnabotulinumtoxinA for Treatment of Moderate to Severe Horizontal Frontalis Lines and Glabellar Lines From the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes From a Phase 3 Double-Blind Study. Authors: Dayan S, et al.
• Simultaneous Treatment of Moderate to Severe Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines With OnabotulinumtoxinA From the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes From a Phase 3 Double-Blind Study. Authors: Dayan S, et al.
• The Psychological Impact of Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines: Qualitative, Patient-Centered Studies. Authors: Brin M, et al.
• JUVÉDERM VOLLURE™ XC Is Safe and Effective for Correcting Nasolabial Folds: Results From a Randomized Controlled Study. Authors: Monheit G, et al.
• JUVÉDERM VOLLURE™ XC Is Safe and Effective for Long-term Correction of Nasolabial Folds: Results From a Multicenter, Randomized, Controlled Study. Authors: Dayan S, et al.
• Lip and Perioral Enhancement With HA Dermal Fillers in Individuals With Skin of Color. Authors: Taylor S, et al.
• VYC-17.5L is Effective for the Treatment of Static and Dynamic Radial Cheek Lines: Results From the BEAM Study. Authors: Ogilvie P, et al.
• ATX-101 (Deoxycholic Acid Injection) Is Effective in Men for Submental Fat Reduction: Results From Randomized Controlled Phase 3 Trials. Authors: Bertucci V, et al.
• Real-World Use of ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat: Final Data From CONTOUR. Authors: Beer K, et al.
• Reduction of Submental Fat Continues Beyond 28 Days After ATX-101 Treatment: Results From a Post hoc Analysis. Authors: Dover J, et al.
• Differential Facial Aesthetic Treatment Considerations for Skin of Color Populations: African American, Asian and Hispanic. Authors: Boyd C, et al.
• Maximizing Panfacial Aesthetic Outcomes: Findings and Recommendations From the HARMONY Study. Authors: Kaminer M, et al.
• Pan-facial Aesthetic Treatment Positively and Significantly Impacts Social Perception. Authors: Dayan S, et al.
• Immediate and Long-Term Efficacy of a Two-Step Topical Hyaluronic Acid Lip Treatment. Authors: Makino E, et al.
• Clinical Efficacy and Tolerability of a Topical HQ-Free Serum on Females with Self-Reported Pregnancy-Induced Facial Melasma. Authors: Makino E, et al.
• Clinical Efficacy and Tolerability of a Cosmetic Growth Factor Serum for Overall Facial Photodamage. Authors: Makino E, et al.
• Combining In-Office Chemical Peel Procedures With Topical Therapy Of A Comprehensive Pigmentation Control Product For Multi-Ethnic Subjects With Moderate To Severe Facial Hyperpigmentation. Authors: Schneider K, et al.

RHOFADE® (oxymetazoline HCl) cream 1% Important Safety Information

Indication

RHOFADE® (oxymetazoline HCl) cream 1% is a prescription medicine used on the skin to treat ongoing facial redness due to rosacea in adults.

Important Safety Information

Before you use RHOFADE® cream, tell your doctor about all your medical conditions, including if you have: heart, blood vessel, or blood pressure problems, or narrow-angle glaucoma (get medical help if these conditions worsen); problems with blood circulation or have had a stroke; Sjögren's syndrome; scleroderma; Raynaud's phenomenon; thromboangiitis obliterans; or irritated skin or open sores on the face.

Tell your doctor about your medications, as use with RHOFADE® cream may cause serious side effects.

The most common side effects at the application site include: skin reactions, worsening of rosacea pimples, itching, redness, and pain.

You may report side effects to the FDA at 1-800-FDA-1088.

Please see full Product Information for RHOFADE^® cream.

ACZONE^® (dapsone) Gel, 7.5% Important Safety Information

Indication
ACZONE^® Gel, 7.5% is approved by the U.S. Food and Drug Administration (FDA) as a prescription medicine used on the skin (topical) to treat acne in people 12 years of age and older.¹

Important Safety Information

Before you use ACZONE^®, tell your doctor about all of your medical conditions, including if you have: glucose-6-phosphate dehydrogenase deficiency (G6PD) or higher than normal levels of methemoglobin in your blood (methemoglobinemia).

Talk to your doctor about any medications you're using including topical benzoyl peroxide (BPO). Use of BPO with ACZONE^® Gel may cause your skin and facial hair to temporarily turn yellow or orange at the site of application.

ACZONE^® Gel 7.5% may cause serious side effects, including:

• A decrease of oxygen in your blood caused by a certain type of abnormal red blood cell (methemoglobinemia). If your lips, nail beds or the inside of your mouth turns grey or blue, stop using ACZONE^® Gel 7.5% and get medical help right away.
• A breakdown of red blood cells (hemolytic anemia) for some people with G6PD deficiency using ACZONE^® Gel 7.5%.
• Stop using ACZONE^® Gel 7.5%, and call your doctor right away if you get any of the following signs and symptoms: back pain, breathlessness, tiredness/weakness, dark-brown urine, fever, or yellow or pale skin.

The most common side effects of ACZONE® Gel 7.5% are dryness and itching of the skin being treated.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Product Information for  ACZONE^®

¹ACZONE® (dapsone) Gel 7.5% U.S. Prescribing Information

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners.

SOURCE Allergan plc

Related Links

http://www.allergan.com